Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes.

Rayman, G, Lumb, A N, Kennon, B, Cottrell, C, Nagi, D, Page, E, Voigt, D, Courtney, H C, Atkins, H, Platts, J, Higgins, K, Dhatariya, K, Patel, M, Narendran, Parth, Kar, P, Newland-Jones, P, Stewart, R, Burr, O and Thomas, S (2020) Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes. Diabetic medicine : a journal of the British Diabetic Association. ISSN 1464-5491. This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs

Full text not available from this repository.

Abstract

The RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial found that dexamethasone 6 mg once per day for 10 days reduced deaths by one-third in ventilated patients and by one-fifth in other patients, receiving oxygen therapy. This equates to the prevention of one death in around eight ventilated patients, or one in around 25 patients requiring oxygen.

Item Type:	Article
Additional Information:	This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs
Subjects:	WC Communicabable diseases WK Endocrine system. Endocrinology
Divisions:	Clinical Support > Immunology
Related URLs:	https://pubmed.ncbi.nlm.nih.gov/32740972...
Depositing User:	Mrs Yolande Brookes
Date Deposited:	28 Aug 2020 15:53
Last Modified:	28 Aug 2020 15:53
URI:	http://www.repository.uhblibrary.co.uk/id/eprint/3391

Actions (login required)

View Item